

Felber M, Steward CG, Kentouche K, et al. Targeted busulfan-based reduced-intensity conditioning and HLA-matched HSCT cure hemophagocytic lymphohistiocytosis. *Blood Adv.* 2020;4(9):1998-2010.

In the serotherapy column in Table 1 on page 2001, for patient 7, “Alemtuzumab” should read “Thymoglobulin.” The error has been corrected in the published article.

---

DOI 10.1182/bloodadvances.2020003085

© 2020 by The American Society of Hematology